Clinical trial · Interventional
Stem Cell Transplant for Hematological Malignancy
Allogeneic Transplant for Hematological Malignancy
NCT00176930CI-TRIAL-00049556terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): replaced by another study ; Trial re-written as MT2015-29
Summary
Brief summary (as posted)
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Hodgkin's Disease | Hodgkin Lymphoma | ALIAS | 0.90 |
| JMML | Juvenile Myelomonocytic Leukemia | ALIAS | 0.90 |
| Leukemia, Lymphocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Lymphocytic, Chronic | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia, Myeloid, Chronic | Leukemia | ONTOLOGY_EXACT | 0.85 |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non-hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Busulfan | Drug | Busulfan | ALIAS |
| CD4+/CD25+ cells | Biological | — | UNRESOLVED |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Equine ATG (ATGAM) | Drug | — | UNRESOLVED |
| Stem Cell Transplant | Biological | Hematopoietic Cell Transplantation | ALIAS |
| Total Body Irradiation | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- type
- EXPERIMENTAL
- label
- PBSC: No TBI
- description
- Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
- interventionNames
- Biological: Stem Cell Transplant
- Drug: Cyclophosphamide
- Drug: Busulfan
- type
- EXPERIMENTAL
- label
- Marrow : No TBI
- description
- Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
- interventionNames
- Biological: Stem Cell Transplant
- Drug: Cyclophosphamide
- Drug: Busulfan
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Donor will be \<75 years of age and in good health. * Recipients will be \< or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment \> or = 90%. * Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if \< 35 years old) at a single HLA A, B, DRB1 locus. * Recipients will be eligible in one of the following disease categories * Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors. * Acute myelocytic leukemia in first or greater remission, or first, second or third relapse. * Acute lymphocytic leukemia in the 2nd or greater bone marrow remission. * High risk children will be transplanted in first remission if they meet criteria * Myelodysplastic syndrome. * Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML)) * Juvenile myelomonocytic leukemia * Chronic lymphocytic leukemia * Advanced non-Hodgkin's (NHL). * Advanced Hodgkin's disease beyond PR2 (\> CR3, \> PR3). * Multiple Myeloma after initial therapy. * Donors and recipients signed informed consent Exclusion Criteria donors and recipients should meet the following test criteria. * required for donors: * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming. * CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed) * required for recipients: * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.
References
Publications (0)
Data not yet available
No reference posted for this study.